Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $215.90 | Total: $1,079.50 |
| 1 | 10 | $182.88 | Total: $1,828.80 |
| 1 | 25 | $154.94 | Total: $3,873.50 |
| 1 | 50 | $132.08 | Total: $6,604.00 |
| 1 | 100 | $114.30 | Total: $11,430.01 |
Overview
HKB99 is a mutant inhibitor of phosphoglycerate mutase 1 (PGAM1), which inhibits the growth and metastasis of non-small cell lung cancer.HKB99 acts synergistically with EGFR inhibitors and assists in the killing of tumors by EGFR inhibitors.HKB99 promotes oxidative stress, which induces alterations in a variety of signaling pathways.HKB99 can be used in the study of metabolism-related diseases.HKB99 can be used in the study of metabolism-related diseases.HKB99 can be used in the study of metabolism-related diseases.
Chemical Properties
| Molecular Formula | C23H18N2O6S |
| Molecular Weight | 450.46 |
| CAS Numbers | 2414908-90-8 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1C=2C=CC=CC2C(=O)C3=C(O)C(O)=C(C=C13)NS(=O)(=O)C4=CC=C(C=C4)N5CCC5 |
Storage and Handling
0C Short Term, -20C Long Term
References
Liang Q, et al. HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. Acta Pharmacol Sin. 2021 Jan;42[1] 115-119.